296 related articles for article (PubMed ID: 32027842)
1. Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study.
Playford EG; Munro T; Mahler SM; Elliott S; Gerometta M; Hoger KL; Jones ML; Griffin P; Lynch KD; Carroll H; El Saadi D; Gilmour ME; Hughes B; Hughes K; Huang E; de Bakker C; Klein R; Scher MG; Smith IL; Wang LF; Lambert SB; Dimitrov DS; Gray PP; Broder CC
Lancet Infect Dis; 2020 Apr; 20(4):445-454. PubMed ID: 32027842
[TBL] [Abstract][Full Text] [Related]
2. Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study.
Sivapalasingam S; Kamal M; Slim R; Hosain R; Shao W; Stoltz R; Yen J; Pologe LG; Cao Y; Partridge M; Sumner G; Lipsich L
Lancet Infect Dis; 2018 Aug; 18(8):884-893. PubMed ID: 29929783
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial.
Clarke DK; Xu R; Matassov D; Latham TE; Ota-Setlik A; Gerardi CS; Luckay A; Witko SE; Hermida L; Higgins T; Tremblay M; Sciotto-Brown S; Chen T; Egan MA; Rusnak JM; Ward LA; Eldridge JH
Lancet Infect Dis; 2020 Apr; 20(4):455-466. PubMed ID: 31952923
[TBL] [Abstract][Full Text] [Related]
4. An observer-blind, randomised, placebo-controlled, phase 1, single ascending dose study of dengue monoclonal antibody in healthy adults in Australia.
Gunale B; Farinola N; Kamat CD; Poonawalla CS; Pisal SS; Dhere RM; Miller C; Kulkarni PS
Lancet Infect Dis; 2024 Jun; 24(6):639-649. PubMed ID: 38408457
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial.
Zhu FC; Wurie AH; Hou LH; Liang Q; Li YH; Russell JB; Wu SP; Li JX; Hu YM; Guo Q; Xu WB; Wurie AR; Wang WJ; Zhang Z; Yin WJ; Ghazzawi M; Zhang X; Duan L; Wang JZ; Chen W
Lancet; 2017 Feb; 389(10069):621-628. PubMed ID: 28017399
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study.
Beigel JH; Voell J; Kumar P; Raviprakash K; Wu H; Jiao JA; Sullivan E; Luke T; Davey RT
Lancet Infect Dis; 2018 Apr; 18(4):410-418. PubMed ID: 29329957
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.
Penn-Nicholson A; Tameris M; Smit E; Day TA; Musvosvi M; Jayashankar L; Vergara J; Mabwe S; Bilek N; Geldenhuys H; Luabeya AK; Ellis R; Ginsberg AM; Hanekom WA; Reed SG; Coler RN; Scriba TJ; Hatherill M;
Lancet Respir Med; 2018 Apr; 6(4):287-298. PubMed ID: 29595510
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
Glund S; Stangier J; Schmohl M; Gansser D; Norris S; van Ryn J; Lang B; Ramael S; Moschetti V; Gruenenfelder F; Reilly P; Kreuzer J
Lancet; 2015 Aug; 386(9994):680-90. PubMed ID: 26088268
[TBL] [Abstract][Full Text] [Related]
10. Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study.
McCarthy JS; Yalkinoglu Ö; Odedra A; Webster R; Oeuvray C; Tappert A; Bezuidenhout D; Giddins MJ; Dhingra SK; Fidock DA; Marquart L; Webb L; Yin X; Khandelwal A; Bagchus WM
Lancet Infect Dis; 2021 Dec; 21(12):1713-1724. PubMed ID: 34715032
[TBL] [Abstract][Full Text] [Related]
11. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.
Yuen MF; Agarwal K; Gane EJ; Schwabe C; Ahn SH; Kim DJ; Lim YS; Cheng W; Sievert W; Visvanathan K; Ruby E; Liaw S; Yan R; Huang Q; Colonno R; Lopatin U
Lancet Gastroenterol Hepatol; 2020 Feb; 5(2):152-166. PubMed ID: 31711752
[TBL] [Abstract][Full Text] [Related]
12. Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study.
Barber BE; Fernandez M; Patel HB; Barcelo C; Woolley SD; Patel H; Llewellyn S; Abd-Rahman AN; Sharma S; Jain M; Ghoghari A; Di Resta I; Fuchs A; Deni I; Yeo T; Mok S; Fidock DA; Chalon S; Möhrle JJ; Parmar D; McCarthy JS; Kansagra K
Lancet Infect Dis; 2022 Jun; 22(6):879-890. PubMed ID: 35247321
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial.
Kibuuka H; Berkowitz NM; Millard M; Enama ME; Tindikahwa A; Sekiziyivu AB; Costner P; Sitar S; Glover D; Hu Z; Joshi G; Stanley D; Kunchai M; Eller LA; Bailer RT; Koup RA; Nabel GJ; Mascola JR; Sullivan NJ; Graham BS; Roederer M; Michael NL; Robb ML; Ledgerwood JE;
Lancet; 2015 Apr; 385(9977):1545-54. PubMed ID: 25540891
[TBL] [Abstract][Full Text] [Related]
14. Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial.
Boxer AL; Qureshi I; Ahlijanian M; Grundman M; Golbe LI; Litvan I; Honig LS; Tuite P; McFarland NR; O'Suilleabhain P; Xie T; Tirucherai GS; Bechtold C; Bordelon Y; Geldmacher DS; Grossman M; Isaacson S; Zesiewicz T; Olsson T; Muralidharan KK; Graham DL; O'Gorman J; Haeberlein SB; Dam T
Lancet Neurol; 2019 Jun; 18(6):549-558. PubMed ID: 31122495
[TBL] [Abstract][Full Text] [Related]
15. Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Anti-IFNAR1 Monoclonal Antibody QX006N: A First-in-Human Single Ascending Dose Study in Healthy Chinese Volunteers.
Li X; Li B; Wang M; Fang M; Lou J; Liu J; Chen H; Ding Y
BioDrugs; 2024 Mar; 38(2):313-321. PubMed ID: 38148466
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study.
Gaudinski MR; Coates EE; Novik L; Widge A; Houser KV; Burch E; Holman LA; Gordon IJ; Chen GL; Carter C; Nason M; Sitar S; Yamshchikov G; Berkowitz N; Andrews C; Vazquez S; Laurencot C; Misasi J; Arnold F; Carlton K; Lawlor H; Gall J; Bailer RT; McDermott A; Capparelli E; Koup RA; Mascola JR; Graham BS; Sullivan NJ; Ledgerwood JE;
Lancet; 2019 Mar; 393(10174):889-898. PubMed ID: 30686586
[TBL] [Abstract][Full Text] [Related]
17. TLR7 agonist RO7020531 versus placebo in healthy volunteers and patients with chronic hepatitis B virus infection: a randomised, observer-blind, placebo-controlled, phase 1 trial.
Yuen MF; Balabanska R; Cottreel E; Chen E; Duan D; Jiang Q; Patil A; Triyatni M; Upmanyu R; Zhu Y; Canducci F; Gane EJ
Lancet Infect Dis; 2023 Apr; 23(4):496-507. PubMed ID: 36509100
[TBL] [Abstract][Full Text] [Related]
18. Vaccination of human participants with attenuated Necator americanus hookworm larvae and human challenge in Australia: a dose-finding study and randomised, placebo-controlled, phase 1 trial.
Chapman PR; Webster R; Giacomin P; Llewellyn S; Becker L; Pearson MS; De Labastida Rivera F; O'Rourke P; Engwerda CR; Loukas A; McCarthy JS
Lancet Infect Dis; 2021 Dec; 21(12):1725-1736. PubMed ID: 34419209
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.
Madhi SA; Cutland CL; Jose L; Koen A; Govender N; Wittke F; Olugbosi M; Meulen AS; Baker S; Dull PM; Narasimhan V; Slobod K
Lancet Infect Dis; 2016 Aug; 16(8):923-34. PubMed ID: 27139805
[TBL] [Abstract][Full Text] [Related]
20. A Phase 1 Single-Ascending-Dose Trial in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravenous PNT001, a Novel Mid-domain Tau Antibody Targeting cis-pT231 Tau.
Luca W; Foster K; McClure K; Ahlijanian MK; Jefson M
J Prev Alzheimers Dis; 2024; 11(2):366-374. PubMed ID: 38374743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
